The more committed life sciences companies are to clinical diversity, the better treatment options they will be able to offer.
Scientific and technological advances are making it easier than ever for life sciences companies to expand clinical trial candidate bases, so, in many cases, they should be able to more accurately reflect their real-world patient population. Learn 5 key considerations for assessing and restructuring clinical trial design and processes to achieve better representation of target populations.
Read the full byline by Guidehouse experts Vijaya Prajwala, Liisa M. Eisenlohr, and Enno Behrendt.